Crizotinib CAS 877399-52-5 Assay ≥99.0% API Tayada Sare
Shanghai Ruifu Chemical Co., Ltd. waa saaraha ugu horreeya ee Crizotinib (CAS: 877399-52-5) oo leh tayo sare.Kiimikada Ruifu waxay bixin kartaa gaarsiinta adduunka oo dhan, qiimo tartan ah, adeeg aad u wanaagsan, tiro yar iyo tiro badan oo la heli karo.Iibso Crizotinib,Please contact: alvin@ruifuchem.com
| Magaca Kiimikada | Crizotinib |
| La mid ah | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3-[1- (2,6-Dichloro-3-Fluoro-phenyl)-ethoxy]-5- (1-Piperidin-4-yl-1H-pyrazol-4-yl) -pyridin-2-ylamine;(R)-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-yl-1H- pyrazol-4-yl)pyridin-2-ylamine |
| Lambarka CAS | 877399-52-5 |
| Heerka Saamiyada | Kaydka, Miisaanka Wax-soo-saarka Ilaa boqollaal Kiilogaram |
| Qaanuunka molecular | C21H22Cl2FN5O |
| Miisaanka Molecular | 450.34 |
| Meesha dhalaalaysa | 192℃ |
| Cufnaanta | 1.47±0.10 g/cm3 |
| Heerkulka Kaydinta | Heerkulka qolka |
| Asal ahaan | Shanghai, Shiinaha |
| Summada | Kiimikada Ruifu |
| Shayga | Tilmaamaha |
| Muuqashada | Caddaan ilaa budo cad-cad |
| Aqoonsiga | By IR, HPLC |
| Cadaynta Xalka | U hoggaansamo Heerka |
| Khasaare xagga qalajinta | ≤1.00% |
| Hadhaaga dabka | ≤0.50% |
| wasakhda la xidhiidha | (waxaa qoray HPLC) |
| Xumaanta Keliya | ≤0.50% |
| Wadarta wasakhda | ≤1.00% |
| Biraha culus | ≤20pm |
| Qiimayn | ≥99.0% |
| Xalalka Haraaga ah | La kulan Tilmaamaha |
| Nolosha shelf | 24 bilood |
| Heerka Imtixaanka | Heerka Ganacsiga |
Xidhmada:Dhalo, bacda bireed ee aluminium, 25kg/Drum kartoonada, ama sida waafaqsan shuruudaha macmiilka.
Xaaladda Kaydinta:Weelka si adag u xidh oo ku kaydi qabow, qalalan (2 ~ 8 ℃) iyo bakhaar hawo wanaagsan leh oo ka fog walxaha aan ku habboonayn.Ka ilaali iftiinka iyo qoyaanka.
Rarida:Ku gaarsii adduunka oo dhan hawo, by FedEx/DHL Express.Bixi keenid degdeg ah oo la isku halayn karo.
Sharaxaada Badbaadada 24/25 - Ka fogow taabashada maqaarka iyo indhaha.
UN IDs UN 3077 9 / PGIII
WGK Germany 3
HS code 2933990099
Heerka Khatarta IRRATANT
Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), waa ATP awood leh oo la xushay oo xakameynaya molecule yar yar ee ALK iyo c-Met.Bishii Agoosto 2011, FDA waxay ogolaatay Crizotinib daaweynta anaplastic lymphoma kinase (ALK) dib u habeyn lagu sameeyay kansarka sambabada aan-unugga yareyn (NSCLC).Crizotinib waa dual ATP tartanka ka hortagga tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) iyo ALK (cellular IC50=20 nM), labaduba waa bartilmaameedyada muhiimka ah ee daaweynta kemotherabi kansarka.Markii crizotinib lagu tijaabiyay xulashada xulashada iyo kinases kale waxaa la ogaaday inuu leeyahay enzyme IC50's gudaha 100-laab dhufashada c-MET ee 13 ee 120 kinases ee la tijaabiyay.Baaritaannada gacanta, crizotinib waxaa la ogaaday inuu ka hortagayo RON (recepteur d'origine nantais) kinase oo leh 10-laab daaqad doorasho oo ka sarreysa c-MET.
Crizotinib (PF-02341066) Crizotinib waa c-Met awood leh iyo ALK inhibitor, qiyamka IC50 ee baaritaanka unuggu waxay ahaayeen 11 nM iyo 24 nM, siday u kala horreeyaan.Sidoo kale waa horjooge awood leh oo ROS1 ah oo leh qiime Ki ka yar 0.025 nM.Crizotinib waxay u horseedi kartaa autophagy khadadka unugyada kansarka sanbabada ee kala duwan iyadoo la joojinayo dariiqa STAT3.
Crizotinib waa xakameyn awood leh oo la xushay oo ah laba-xakameeyaha kala-guurka mesenchymal-epithelial (c-MET) kinase iyo anaplastic lymphoma kinase (ALK).Crizotinib waa wakiilka antitumor ee suurtogalka ah.Bishii Agoosto 2011, FDA waxay ogolaatay crizotinib daaweynta anaplastic lymphoma kinase (ALK) dib u habeyn lagu sameeyay kansarka sambabada aan-unugga yareyn (NSCLC).
Crizotinib (Xalkori (R), Pfizer), oo la ansixiyay 2011, ayaa ahaa xannibadihii ugu horreeyay ee la oggolaado ee bartilmaameedsada anaplastic lymphoma kinase (ALK).ROS protooncogene 1-encoded kinase (ROS1) ee fasalka tyrosine kinase insulin receptor iyo MET proto-oncogene-encoded kinase ee hepatocyte factor reseptor (HGFR) waa kinases kale oo lala beegsaday crizotinib. Markii la ansixiyay 2011, crizotinib wuxuu ahaa kii ugu horreeyay dawada si gaar ah loogu beegsanayo bukaannada NSCLC.Si kastaba ha ahaatee, iska caabinta crizotinib ayaa sida caadiga ah lagu arkay qiyaastii 8 bilood ka dib codsiga bilawga ah iyo in ka badan kala badh bukaannada crizotinib-daaweeyay waxay la kulmeen waxyeelooyinka caloosha.Sannadkii 2016, Crizotinib waxaa sidoo kale loo oggolaaday ROS1-positive NSCLC ee FDA.
Crizotinib (Xalkori) waa daaweeyaha afka laga qaato ee tyrosine kinase inhibitor oo loogu talagalay daawaynta bukaanada qaba kansarka sambabada unugyada aan yarayn ama metastatic (NSCLC).Dhibaatooyinka caadiga ah ee isticmaalka Xalkori waxaa ka mid ah caabuqa neef-mareenka sare, lallabbo, matag, calool xanuun, rabitaanka cuntada oo yaraada, hurdo la'aan, dawakhaad, dareen daal, shuban, calool-istaag, finan ama cuncun, calaamadaha qabow (sanka oo dhegta, hindhiso, cune xanuun), kabuubyo ama xiirid, ama barar gacmahaaga ama cagahaaga ah.
